EGFR Inhibitors Extend Their Reach in Lung Cancer
Recent advances in EGFR inhibition include combinations to overcome resistance and approvals for newly diagnosed or early-stage lung cancers.
Progress Against Cancer
Recent advances in EGFR inhibition include combinations to overcome resistance and approvals for newly diagnosed or early-stage lung cancers.
A recent study on the prevalence of cancer across different vertebrate species may provide insights into cancer mechanisms in humans.
At the AACR Conference on the Science of Cancer Health Disparities, researchers shared results from interventions designed to help close cancer care gaps.
Long-term monitoring can catch side effects in childhood cancer survivors, and breast cancer screening rates remain low among transgender people.
This month, the editors selected studies comparing CAR T therapies for large B-cell lymphoma, assessing a new type of blood test for colorectal cancer detection, and more.
The therapeutic was approved for certain patients with Philadelphia chromosome-positive chronic myeloid leukemia. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to asciminib (Scemblix) for adults with newly diagnosed, Philadelphia chromosome (Ph)-positive...
Asian American and Pacific Islander women face rising rates of early-onset breast cancer, and the risk for dying of COVID-19 is twice as high in people living with cancer.
Animals with longer gestation times may have fewer cancers, but the way traits relate to cancer risk is complex. Cancer occurs in animals as well as in humans, at widely varying rates among different...
The FDA approved the claudin 18.2-targeted therapy Zolbetuximab-clzb for some gastric and gastroesophageal junction cancers. The U.S. Food and Drug Administration (FDA) has approved zolbetuximab-clzb (Vyloy) plus a chemotherapy regimen consisting of fluoropyrimidine- and platinum-containing...
Immunotherapy lowers risk of side effects in advanced lymphoma, and an extra course of chemotherapy improves survival in cervical cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More